Skip to content

Short squeeze alert for August 14th: Two stocks poised for lift-off

Short squeeze alert for August 14th: Two stocks poised for lift-off
Kliment Dukovski

Stocks that are heavily shorted have the potential to skyrocket as traders are forced to cover their short positions by buying back the stock. This can be an extremely profitable strategy if you find the right stock at the right time.

Because the interest for shorted stocks remains, Finbold analyzed the most shorted stocks this year on August 14 and selected the two that have a high potential for lift-off.

BioXcel Therapeutics

BioXcel Therapeutics (NASDAQ: BTAI) is a biopharmaceutical company that uses AI in its approach to developing medicine in neuroscience and immuno-oncology.

The company saw an increase in short interest by 69% in July, making a total of 43% short of the company’s floating shares. This is one of the most-shorted stocks as of July.

Morningstar’s quantitative equity report places a fair value of $17.4 per share. With the current share price of $7.4, that’s a 135% increase should this price be reached. If it happens, this is likely to cause a massive short squeeze.

Morningstar quantitative equity report. Source: Interactive Brokers Fundamentals Explorer

BioXcel announced it intends to cut 50% of its cash burn in its Q2 earnings report on August 14. The company will also reduce its workforce to 80 employees from 190. This should help BioXcel have cash reserves until mid-2024.

The company also announced it would shift its commercial strategy to focus on deals with large hospital systems.

Allogene Therapeutics

Allogene Therapeutics (NASDAQ: ALLO) is a clinical-stage immuno-oncology company. The company aims to develop genetically engineered allogeneic T-cell products for treatment of cancer.

This is the most shorted stock as of July, with over 54% of float shorted.

Morningstar’s analyst equity report has a relatively high fair value estimate of $8 per share. That’s a 90% increase from the current price of $4.2.

Morningstar analyst equity report. Source: Interactive Brokers Fundamentals Explorer

Allogene is down 27% year to date, while BioXcel is down 65% during the same period. Both are heavily outperformed by the S&P 500’s 17%. 

Buy stocks now with Interactive Brokers – the most advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Services

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.